ESPR vs. CRBP, BMEA, ORGO, ANNX, NGNE, MRSN, HRTX, RVNC, ADCT, and LRMR
Should you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Corbus Pharmaceuticals (CRBP), Biomea Fusion (BMEA), Organogenesis (ORGO), Annexon (ANNX), Neurogene (NGNE), Mersana Therapeutics (MRSN), Heron Therapeutics (HRTX), Revance Therapeutics (RVNC), ADC Therapeutics (ADCT), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical preparations" industry.
Corbus Pharmaceuticals (NASDAQ:CRBP) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk.
Corbus Pharmaceuticals has higher earnings, but lower revenue than Esperion Therapeutics. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.
Esperion Therapeutics received 168 more outperform votes than Corbus Pharmaceuticals when rated by MarketBeat users. Likewise, 69.74% of users gave Esperion Therapeutics an outperform vote while only 66.61% of users gave Corbus Pharmaceuticals an outperform vote.
Corbus Pharmaceuticals has a net margin of 0.00% compared to Corbus Pharmaceuticals' net margin of -179.87%. Corbus Pharmaceuticals' return on equity of 0.00% beat Esperion Therapeutics' return on equity.
64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 4.0% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Corbus Pharmaceuticals presently has a consensus target price of $52.00, indicating a potential upside of 39.60%. Esperion Therapeutics has a consensus target price of $9.33, indicating a potential upside of 357.52%. Given Corbus Pharmaceuticals' higher possible upside, analysts clearly believe Esperion Therapeutics is more favorable than Corbus Pharmaceuticals.
In the previous week, Esperion Therapeutics had 9 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 11 mentions for Esperion Therapeutics and 2 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.04 beat Esperion Therapeutics' score of -0.33 indicating that Esperion Therapeutics is being referred to more favorably in the news media.
Corbus Pharmaceuticals has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.
Summary
Esperion Therapeutics beats Corbus Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Esperion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Esperion Therapeutics Competitors List
Related Companies and Tools
